

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>January 6, 2010</u>  (use as many sheets as necessary)				Application Number		10/584,345
				Filing Date		December 24, 2004
				First Named Inventor		Nobuaki TAKAHASHI
				Art Unit		1644
				Examiner Name		Phillip GAMBEL
Sheet	1	of	2	Attorney Docket Number		081356-0262

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	F1	EP 1391464 A1	02-25-2004	KIRIN BEER KABUSHIKI KAISHA	English language equivalent of F3	
	F2	WO 00/75348 A1	12-14-2000	SEATTLE GENETICS INC.	English language equivalent of F4	
	F3	WO 02/088186 A1	11-07-2002	KIRIN BEER KABUSHIKI KAISHA		
	F4	JP 2003-519470 T	06-24-2003	SEATTLE GENETICS INC.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	F5	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc", 2000, <i>J. Immunol.</i> , 164(8), pp 4178-4184.	
	F6	TAO et al., "Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation", 1993, <i>J. Exp. Med.</i> , 178(2), pp. 661-667.	
	F7	MORGAN et al., "The N-terminal End of the C <sub>H</sub> 2 domain of Chimeric Human IgG1 anti-HLA-DR is Necessary for C1q, Fc gamma RI and Fc gamma RII binding", 1995, <i>Immunology</i> , 86(2), pp. 319-324.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>January 6, 2010</u>  (use as many sheets as necessary)		<b>Application Number</b>	10/584,345
		<b>Filing Date</b>	December 24, 2004
		<b>First Named Inventor</b>	Nobuaki TAKAHASHI
		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Phillip GAMBEL
<b>Sheet</b>	2	<b>of</b>	2
		<b>Attorney Docket Number</b>	081356-0262

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	F8	REDDY, et al., "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4", 2000, <i>J. Immunol.</i> , 164, pp. 1925-1933.	
	F9	ANGAL et al., "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody", 1993, <i>Mol. Immunol.</i> 30(1), pp. 105-108.	
	F10	XU et al., "Residue at Position 331 in the IgG1 and IgG4 C <sub>H</sub> 2 Domains Contributes to their Differential Ability to Bind and Activate Complement", 1994, <i>J. Biol. Chem.</i> , 269(5), pp. 3469-3474.	
	F11	TAO et al., "The Differential Ability of Human IgG1 and IgG4 to Activate Complement is Determined by the COOH-terminal Sequence of the C <sub>H</sub> 2 domain", 1991, <i>J. Exp. Med.</i> , 173(4), pp. 1025-1028.	
	F12	IDUSOGIE et al., "Engineered Antibodies with Increased Activity to Recruit Complement", 2001, <i>J. Immunol.</i> , 166(4), pp. 2571-2575.	
	F13	AALBERSE et al., "IgG4 Breaking the Rules", 2002, <i>Immunology</i> , 105(1), pp. 9-19.	
	F14	NEWMAN et al., "Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4+ T Cells in Chimpanzees", 2001, <i>Clinical Immunology</i> , 98(2), pp. 164-174.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.